These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33910194)

  • 1. Serum Cardiac Biomarkers in Asymptomatic Hemodialysis Patients: Role of Soluble Suppression of Tumorigenicity-2.
    Mancianti N; Maresca B; Palladino M; Salerno G; Cardelli P; Menè P; Barberi S
    Blood Purif; 2022; 51(2):155-162. PubMed ID: 33910194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of high-sensitive cardiac troponin I in asymptomatic chronic hemodialysis patients.
    Maresca B; Manzione A; Moioli A; Salerno G; Cardelli P; Punzo G; Barberi S; Menè P
    J Nephrol; 2020 Feb; 33(1):129-136. PubMed ID: 31020624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive value of early detection of hs-cTnI and sST2 for secondary cardiac damage in severe acute organophosphorus pesticide poisoning].
    Liu XT; Wang L; Chen J; Qi HN; Ma GY
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Apr; 38(4):241-245. PubMed ID: 32447883
    [No Abstract]   [Full Text] [Related]  

  • 4. Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates.
    Keddis MT; El-Zoghby Z; Kaplan B; Meeusen JW; Donato LJ; Cosio FG; Steidley DE
    PLoS One; 2017; 12(7):e0181123. PubMed ID: 28704488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study.
    Wang Z; Chen Z; Yu H; Ma X; Zhang C; Qu B; Zhang W; Chen X
    Ren Fail; 2020 Nov; 42(1):523-530. PubMed ID: 32460670
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study.
    Sabbatinelli J; Giuliani A; Bonfigli AR; Ramini D; Matacchione G; Campolucci C; Ceka A; Tortato E; Rippo MR; Procopio AD; Moretti M; Olivieri F
    Cardiovasc Diabetol; 2022 Sep; 21(1):180. PubMed ID: 36088327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain.
    Marino R; Magrini L; Orsini F; Russo V; Cardelli P; Salerno G; Hur M; Di Somma S;
    Ann Lab Med; 2017 Mar; 37(2):137-146. PubMed ID: 28029000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of High-sensitivity Cardiac Troponin I and Soluble Suppression of Tumorigenicity-2 in Surgical Intensive Care Unit Patients Undergoing Non-cardiac Surgery.
    Yang HS; Hur M; Yi A; Kim H; Kim J
    Ann Lab Med; 2018 May; 38(3):204-211. PubMed ID: 29401554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study.
    Zhang Z; Shen B; Cao X; Liu Z; Chen X; Nie Y; Yu J; Zou J; Ding X
    Blood Purif; 2017; 43(1-3):37-45. PubMed ID: 27875808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction.
    Plawecki M; Morena M; Kuster N; Chenine L; Leray-Moragues H; Jover B; Fesler P; Lotierzo M; Dupuy AM; Klouche K; Cristol JP
    Mediators Inflamm; 2018; 2018():3952526. PubMed ID: 30402040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST2 elevation in heart failure, predictive of a high early mortality.
    Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
    Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction.
    Sugano A; Seo Y; Ishizu T; Sai S; Yamamoto M; Hamada-Harimura Y; Machino-Ohtsuka T; Obara K; Nishi I; Aonuma K; Nogami A
    J Cardiol; 2019 Apr; 73(4):326-332. PubMed ID: 30580891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble ST2 and troponin I combination: Useful biomarker for predicting development of stress cardiomyopathy in patients admitted to the medical intensive care unit.
    Yang HS; Kim HJ; Shim HJ; Kim SJ; Hur M; Di Somma S;
    Heart Lung; 2015; 44(4):282-8. PubMed ID: 26077689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
    Dieplinger B; Egger M; Haltmayer M; Kleber ME; Scharnagl H; Silbernagel G; de Boer RA; Maerz W; Mueller T
    Clin Chem; 2014 Mar; 60(3):530-40. PubMed ID: 24401186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.
    Li F; Xu M; Fu M; Cui X; Lian Z; Xin H; Zhou J; Ge J
    BMC Cardiovasc Disord; 2021 Aug; 21(1):396. PubMed ID: 34404341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
    Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
    Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy.
    Weinmann K; Werner J; Koenig W; Rottbauer W; Walcher D; Keßler M
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31731547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of brain natriuretic peptide concentrations to left ventricular function and adverse outcomes in children with end-stage renal disease undergoing hemodialysis.
    Ouali S; Bougmiza I; Abroug S; Omezzine A; Ben Salem H; Neffeti E; Remedi F; Bouslema A; Harabi A; Boughzela E
    Pediatr Cardiol; 2011 Jun; 32(5):568-77. PubMed ID: 21336977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.